We document caspase-dependent cell death in patient derived Ph+ALL lines after treatment with ErbB TKIs alone and in combination with BCR/ABL-directed TKI, providing impetus for the clinical testing of this strategy for ErbB2-expressing Ph+ALL. The gene discussed is EGFR; the disease is acute lymphoblastic leukemia.